Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
On Tuesday, TD Cowen analysts maintained a positive outlook on Stryker Corporation (NYSE:SYK), reiterating a Buy rating and a price target of $435.00. The firm’s analysts anticipate that Stryker will meet its first-quarter targets, bolstered by robust momentum across its units. With a market capitalization of $131 billion, Stryker currently trades at a P/E ratio of 42.8, indicating a premium valuation. According to InvestingPro data, the company maintains a "GREAT" financial health score, supported by strong cash flows and moderate debt levels.
Stryker, a medical technology company, has entered 2025 with high expectations for organic growth. Analysts at TD Cowen believe that the company is well-positioned to meet or even exceed the consensus growth estimate of 8.4% for the first quarter. This confidence is based on strong trends in elective procedure volumes and capital purchases, which have continued to show strength. The company’s recent performance supports this outlook, with revenue growing 10.2% in the last twelve months to $22.6 billion.
The analysts also suggest that Stryker’s first-quarter revenue performance may not only meet but could potentially lead to a reaffirmation of the company’s organic sales growth guidance for 2025. They also do not discount the possibility of Stryker raising the midpoint of its organic revenue growth guidance range, a move the company has made following first-quarter results in previous years. With the next earnings report due on May 1st, InvestingPro subscribers can access detailed financial metrics and 12 additional ProTips to better evaluate Stryker’s growth trajectory.
Historically, Stryker has adjusted its growth forecasts upward after the first quarter. For instance, following the first quarter of 2024, the company increased its organic growth forecast to a range of 8.5% to 9.5%, up from 7.5% to 9.0%. Similarly, after the first quarter of 2023, Stryker raised its guidance to 8.0% to 9.0% from the earlier range of 7.0% to 8.5%. The same underlying factors that prompted these past increases, such as solid procedure volumes and capital spending trends, are present this year and could support an improved forecast.
In their commentary, TD Cowen analysts highlighted the continuous momentum Stryker has demonstrated, which they believe will contribute to achieving the Street forecasts. The analysts concluded by reiterating their Buy rating, signaling their confidence in Stryker’s performance as the first quarter of 2025 comes to a close.
In other recent news, Stryker Corporation has completed the sale of its U.S. spinal implants division to Viscogliosi Brothers, LLC, forming VB Spine, LLC. This strategic divestiture aligns with Stryker’s focus on innovation and long-term growth. Additionally, Stryker has nominated Emmanuel "Manny" Maceda to its board of directors, with the election set for May 2025. Maceda, the Chairman of Bain & Company, is recognized for his extensive experience in corporate transformation.
In terms of analyst perspectives, Needham has reiterated a Buy rating for Stryker, maintaining a price target of $442.00, following the acquisition of Inari Medical (TASE:BLWV). This acquisition is expected to slightly affect Stryker’s operating margin but improve its gross margin over time. RBC Capital also maintained an Outperform rating with a $435.00 price target, citing strong procedure volumes and a positive outlook for 2025. Piper Sandler holds an Overweight rating with a $420.00 target, forecasting robust growth in procedure volumes and market share gains for Stryker through 2027. These developments highlight Stryker’s strategic moves and potential for continued growth in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.